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The metabolism and genotoxicity of the carcinogenic myco-
toxin, aflatoxin B1 (AFB), was studied in the lower eukaryotic
yeast Saccharomyces cerevisiae. Recombinant strains of yeast were
engineered to express human cDNAs for CYP1A1, CYP1A2, and
microsomal epoxide hydrolase (mEH). Coexpression of mEH with
CYP1A1 or CYP1A2 resulted in significant decreases in measure-
ments of AFB genotoxicity. In cells expressing CYP1A2 and mEH,
the level of AFB-DNA adducts was decreased by 50% relative to
cells expressing CYP1A2 alone. Mitotic recombination, as assayed
by gene conversion at the trp5 locus, was diminished by 50% or
greater in cells coexpressing mEH and CYP1A2 compared to
CYP1A2 alone. The mutagenicity of AFB in the Ames assay was
also decreased by approximately 50% when AFB was incubated
with microsomes containing CYP1A1 or CYP1A2 and mEH ver-
sus CYP1A1 or CYP1A2 alone. The biotransformation of AFB by
CYPs is known to involve the generation of a reactive epoxide
intermediate, AFB-8,9-epoxide, but previous direct biochemical
and kinetic studies have failed to demonstrate any functional role
for mEH in AFB detoxification. By reconstructing a metabolic
pathway in intact yeast, we have shown, for the first time, that
mEH may play a role in mitigating the carcinogenic effects of
AFB.
Key Words: aflatoxin B1; microsomal epoxide hydrolase; cyto-
chrome P450; genotoxicity; Saccharomyces cerevisiae.
The aflatoxins are a structurally related group of mycotoxins
that are found in grains and cereals stored under conditions
favoring growth of fungal Aspergillus spp. (reviewed by Eaton
and Heinonen, 1997). The most potent compound is aflatoxin
B1 (AFB), a known hepatocarcinogen in numerous animal
species. Epidemiological evidence implicates AFB in develop-
ment of hepatocellular carcinoma (HCC) in humans (Eaton and
Heinonen, 1997). Aflatoxin B1 must be biotransformed by
cytochrome P450 (CYP) enzymes to the reactive intermediate
AFB-8,9-epoxide (AFBO) to exert its carcinogenic effect.
There are two stereroisomers of AFBO (endo- and exo-), and it
is exo-AFBO that is capable of reacting with DNA, preferen-
tially producing N7-guanine adducts. Significant species dif-
ferences exist in susceptibility to AFB-induced carcinogenesis.
For example, rats are highly sensitive, whereas mice are quite
resistant. The resistance of mice to AFB hepatocarcinogenicity
appears to be due solely to the constitutive expression of a
specific form of glutathione S-transferase (GST), mGSTA3-3,
with unusually high catalytic activity toward AFBO (Buetler et
al., 1992). While conjugation to glutathione by GSTs is one
pathway for AFBO elimination, another potential mechanism
is hydrolysis of AFBO to the corresponding dihydrodiol by
microsomal epoxide hydrolase (mEH) that could then serve as
a substrate for aflatoxin-aldehyde reductase (Ellis et al., 1993).
However, while early studies (Ch’ih et al., 1983a,b) support a
role for mEH in AFB detoxification, subsequent direct bio-
chemical and kinetic studies (Guengerich et al., 1996; Johnson
et al., 1997b; Wilson et al., 1997) suggest no role for mEH in
AFB metabolism. As water will rapidly and spontaneously
react with exo-AFBO (t1/2 1 s) (Johnson et al., 1996), enzy-
matic hydrolysis by mEH has been presumed to be insignifi-
cant. However, an epidemiological study by McGlynn et al.
(1995) reported a statistical association between risk of HCC
and occurrence of a polymorphic variant of mEH with some-
what lower activity due to protein destabilization (Hassett et
al., 1994; Omiecinski et al., 2000). Previous epidemiological
studies have found that polymorphic variants of mEH are
associated with differences in risk for several types of cancer in
individuals exposed to polycyclic aromatic hydrocarbons
(PAHs). Unlike metabolism of AFB by mEH, the role of mEH
in PAH metabolism involves generation of more reactive spe-
cies such as benzo[a]pyrene-diolepoxide. Cortessis et al.
(2001) found that a high-activity allele of mEH was associated
with increased risk of colorectal adenoma in cigarette smokers,
while Zhou et al. (2001) found that the low-activity allele
examined in the McGlynn et al. (1995) study was a protective
factor against lung cancer in heavy smokers and a risk factor in
nonsmokers. Thus, the idea that differences in mEH activity
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may alter the development of xenobiotic-induced cancer is
reasonable based on human population studies.
Because it is possible that enzymatic hydrolysis could be
important in the lipid microenvironment, where the reactive
epoxide is formed in the intact cell, we sought to re-examine
the role of mEH in AFB genotoxicity by heterologous expres-
sion in the eukaryotic organism, S. cerevisiae. By reproducing
the enzymatic pathway of bioactivation by human CYP1A
enzymes coupled with coexpression of mEH, we could directly
examine mEH function without membrane reconstitution, be-
cause both CYP1A and mEH enzymes colocalize in yeast
endoplasmic reticulum (Eugster and Sengstag, 1993). In this
study we were able to show that mEH does have a functional
role in AFB detoxification, as measured by DNA adduct for-
mation, mitotic recombination, and Ames assay mutagenicity.
Our data provide an example of the strength of a eukaryotic
yeast expression system for studying the role of biotransfor-
mation enzymes in the production and elimination of reactive
intermediates in intact eukaryotic cells.
MATERIALS AND METHODS
Chemicals and enzymes. AFB and AFM were purchased from Sigma
Chemical Co. (St. Louis, MO). [3H] AFB (16 Ci/mmol) was purchased from
Moravek Biochemicals (Brea, CA). HPLC grade solvents were purchased from
J. T. Baker (Philipsburg, NJ). Yeast synthetic and complete media were
purchased from BIO 101 (Vista, CA). Acrylamide and Bradford reagent were
purchased from BioRad (Hercules, CA). The CYP1A antibody was supplied
by Oxford Biomedical Research (Oxford, MI), and the mEH antibody was a
generous gift from Dr. Curtis Omiecinski, University of Washington. Alkaline
phosphatase-coupled secondary antibodies were purchased from Jackson Im-
munoresearch Laboratories, Inc. (West Grove, PA). Chemiluminescent sub-
strate CSPD was purchased from Tropix (Bedford, MA). Restriction enzymes
were all purchased from New England Biolabs (Beverly, MA).
Yeast strains. The parental S. cerevisiae strain YHE2 (MATa/MATa,
ade2-40/ade2-119, trp5-12/trp5-27, ilv1-92/ilv1-92, ura3D5/ura3D5) and the
transformed strains expressing human cDNAs have been previously described
(Eugster and Sengstag, 1993; Eugster et al., 1990) (except for pHE13 and
pEK30) and are listed as follows: pDP34-control strain with no cDNA;
pHE5-mEH; pHE10-CYP1A1; pHE12-CYP1A1/mEH coexpression; pHE36-
CYP1A2; pHE13-CYP1A2/mEH coexpression; and pEK30-CYP1A2/DmEH.
The yeast were transformed by standard methods (Schiestl and Gietz, 1989)
and cultured in minimal synthetic media lacking uracil.
Plasmid constructs. All the plasmids used in this study have been de-
scribed (Eugster and Sengstag, 1993) except for pHE13 and pEK30. For
pHE13, the vector containing mEH (pHE5) was linearized with Sac I and an
expression cassette for CYP1A2 was excised from pHE36 as a 2-kb Sac-I
fragment and ligated into the Sac I-site of pHE5. The plasmid pEK30 is
identical to pHE13 except that residue 226 of mEH was mutagenized from
aspartic acid to glycine; a mutation known to abolish activity in rat mEH
(Arand et al., 1999). The single base-pair change was introduced by site-
directed mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA) and
the following primer, CATTCAAGGAGGGGgCTGGGGGTCCC, and its
complement (mutant base shown in lower case). The mEH expression cassette
was excised from pHE5 as a 2.2 Kb Sac I/Sal I fragment and ligated into these
same sites in pBluescript (Stratagene). After site-directed mutagenesis, the
entire cassette was resequenced to verify the presence of the mutation and
absence of any other nucleotide changes. The mEH cassette was then ligated
into the Sac I/Sal I sites of pDP34. The CYP1A2 cassette was then cloned into
the Sac I site as previously described for pHE13.
Yeast microsomes. Microsomes were prepared as previously described
(Sengstag and Wu¨rgler, 1994) and aliquots snap frozen in liquid nitrogen and
stored at –80°C prior to use. Protein concentrations were determined with
Bradford reagent (BioRad) with bovine serum albumin as the standard. Het-
erologous microsomal P450 content was measured by the method of Omura
and Sato (1964).
Enzyme assays. The catalytic activity of the microsomes towards AFB
was determined as described by Gallagher et al. (1994). Briefly, approximately
1 mg of yeast microsomal protein, 500 mg of a 2:1 (v:v) mixture of rat:mouse
hepatic cytosol (to quantitatively capture the reactive AFB-epoxide as the
glutathione conjugate, Gallagher et al., 1994), 1 mM NADPH and 5 mM
reduced glutathione in 0.1 M potassium phosphate, pH 7.2 were mixed in a
total volume of 240 ml. After a 5-min preincubation at 37°C, the reaction was
started by the addition of 10 ml of AFB dissolved in dimethysulfoxide, for a
final concentration of 128 mM as determined by UV spectrophotometric
analysis of stock solutions (Busby and Wogan, 1984). The reactions were
allowed to proceed at 37°C for 10 min and then terminated by addition of 250
ml ice-cold methanol containing 1% trifluoroacetic acid and AFG1 (10 mM) as
an internal standard. AFB metabolites were separated by reversed-phased,
high-performance liquid chromatography as previously described (Monroe and
Eaton, 1987) and measured by UV detection. Microsomal epoxide hydrolase
activity for cis-stilbene oxide (CSO) was performed as described by Gill et al.
(1983) with the following modifications. Yeast microsomes were diluted in 10
mM potassium phosphate buffer, pH 7.4 for a final protein concentration of 1
mg/ml in a 100 ml reaction volume. The microsomes were incubated for 5 min
at 37°C and then 1 ml of [3H] CSO stock solution was added for a final
concentration of 50 mM [3H] CSO (specific activity ;10 mCi/mmol). After 20
min at 37°C, the reactions were stopped by addition of 200 ml iso-octane
followed by vortexing; aliquots of the aqueous phase were analyzed by liquid
scintillation counting to quantitate the diol product.
Immunoblotting. Yeast whole-cell extracts or microsomal protein frac-
tions were separated by SDS-PAGE and transferred to Immobilon P mem-
branes (Millipore Corp., Bedford, MA). Nonspecific binding was blocked with
5% BLOTTO dissolved in phosphate-buffered saline containing 0.1% TWEEN
20. Primary antibodies against either human mEH or rabbit CYP1A were
diluted in blocking buffer 1:15,000 or 1:100, respectively. Binding of antibody
to antigen was detected with alkaline phosphatase-conjugated secondary anti-
body and visualized by exposure to X-Omat AR™ film (Eastman Kodak,
Rochester, NY) using chemiluminescent CSPD substrate.
Trp recombination test. The homologous recombination between the
trp5-12/trp5-27 alleles was performed as previously described (Sengstag and
Wu¨rgler, 1994). Briefly, yeast were grown to the exponential phase, washed in
sodium phosphate buffer (100 mM, pH 7.4) and then resuspended in buffer at
a concentration of 108 cells/ml. Cells were then exposed to AFB or AFM in
DMSO at a final concentration of 5% v/v DMSO for 4 h at 30°C, centrifuged
and washed twice with tryptophan-deficient media before plating on agar
plates lacking tryptophan. Trp1 convertants were scored after 3 days of growth
at 30°C. The conversion frequency was calculated by comparing it to the
number of colonies that grew on complete (YPD) media plates (after diluting
the cell cultures 1:40,000 in media, to obtain plating densities easily counted).
AFB-DNA adduct formation. Exponentially growing yeast were har-
vested and 0.05 OD units were inoculated into 0.5 ml 100 mM sodium
phosphate buffer, pH 7.4 containing [3H] AFB (specific activity 18.6 Ci/mmol)
dissolved in methanol for a final solvent concentration of 1.7% (v:v). The cells
were incubated at 30°C for 6 h, protoplasts prepared as described (Sengstag
and Wu¨rgler, 1994), and then total nucleic acid was isolated by alkaline lysis
followed by ethanol precipitation. Cellular RNA was removed by treatment
with 0.2 mg/ml RNase A and then extracted with phenol/chloroform, followed
by ethanol precipitation. The DNA was quantified by UV absorption and
adducts were measured by liquid scintillation counting.
Ames assay. The Salmonella typhimurium strain TA98 (hisD3052, rfa,
DuvrB, pKM101) was used to assay the mutagenicity of AFB metabolized by
yeast microsomes as described previously (Sengstag and Wu¨rgler, 1994). In
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brief, an overnight culture of TA98 was harvested and resuspended in 150 mM
potassium chloride, pH 7.4; 100 ml of bacteria were then added to 700 ml of
an NADPH-regenerating system (containing 150 mM potassium phosphate,
pH 7.4, 0.75 mM NADP1, 15 mM glucose 6-phosphate, 10 mM magnesium
chloride and 10 units glucose 6-phosphate dehydrogenase), followed by 200
mg of yeast microsomes and subsequent addition of 30 ml of AFB. The cell
mixture was incubated for 20 min at 37°C before 2 ml of top agar was added
and the mixture poured onto minimal plates. The revertant colonies were then
scored after incubation at 37°C for 2 days.
Statistical analysis. All data are presented as mean 6 SEM and are
derived from triplicate cultures of at least duplicate experiments. Results were
compared by one-way ANOVA and Tukey-Kramer multiple comparisons test,
using the statistical program InStat for the Macintosh (Graphpad Software Inc.,
San Diego, CA). A p # 0.05 was considered significant.
RESULTS
The expression profiling for the recombinant yeast strains
used in this study are shown by Western blot in Figure 1.
Microsomal proteins (20 mg/lane) were separated by SDS–
PAGE on duplicate 10% polyacrylamide gels and then probed
with either an antibody raised against rabbit CYP1A protein
from 3-methylcholanthrene induced liver or an antipeptide
antibody raised against human mEH (amino acids 42–60). The
level of immunoreactive CYP1A1 protein was slightly higher
in CYP1A1/mEH coexpressor compared to CYP1A1 alone,
while CYP1A2 was uniform except for one clone, designated
CYP1A2hi/mEH, which had somewhat higher levels. The mEH
protein levels exhibited some variation between strains with
the site-directed inactive mutant of mEH (CYP1A2/DmEH)
having lower amounts of immunoreactive mEH protein. How-
ever, this makes little practical difference because the protein
lacks any catalytic activity. In addition to determining expres-
sion by Western blot, we measured heterologous P450 content
and specific activity towards AFB for microsomes purified
from recombinant yeast strains. The yeast strain transformed
with the vector containing no human cDNAs gave no signal by
CO difference spectra nor was there measurable AFB-oxidiz-
ing activity in microsomes purified from this strain. While
Western-blot analysis suggested differences in CYP1A1 con-
tent, the specific activity towards AFB, as measured by forma-
tion of the hydroxylated metabolite aflatoxin M1 (AFM), was
similar (Table 1). Likewise, P450 content did not significantly
differ between yeast expressing CYP1A1 alone or in conjunc-
tion with mEH. For yeast expressing CYP1A2, specific activity
towards AFB for generation of either AFM or AFBO (as
measured by the glutathione-conjugate AFB-GSH) were sim-
ilar for all the strains, with the exception of a single clone of
CYP1A2/mEH coexpressor that had approximately twice as
much P450 content as measured by CO difference spectra. This
particular clone is referred to as CYP1A2hi/mEH. It should be
noted that several other clones of CYP1A2/mEH were ana-
lyzed and none of them had levels as high as CYP1A2hi/mEH
but were similar to CYP1A2 or CYP1A2/mEH clones. When
FIG. 1. Western-blot analysis of heterologous expression in purified mi-
crosomes. Negative control microsomes are in the first lane followed by the
indicated cDNA expressing strains. CYP1A2hi/mEH represents the strain with
approximately doubled expression of CYP1A2 relative to CYP1A2 or
CYP1A2/mEH while CYP1A2/DmEH is the mutated form of mEH lacking
any catalytic activity. Duplicate gels were run for the mEH antipeptide anti-
body and polyclonal CYP1A antibody and each lane contains 20 mg of
microsomal protein.
TABLE 1
Analysis of Heterologous P450 Content, AFB Metabolism, and CSO Activity of Yeast Microsomes
Expressing Human CYP1A and mEH Enzymes
CYP1A1 CYP1A1 (mEH) CYP1A2 CYP1A2 (mEH) CYP1A2h (mEH) CYP1A2 (DmEH)
AFMa 402 6 39 368 6 29 49 6 5 48 6 5 75 6 6 52 6 4
(10,993 6 1066) (10,595 6 833) (3525 6 36) (3750 6 39) (3086 6 16) (3939 6 30)
AFBOa,b 1.8 6 0.5 2.6 6 1.0 46 6 2 44 6 2 78 6 2 51 6 2
(50 6 14) (74 6 29) (3303 6 140) (3458 6 170) (3207 6 79) (3864 6 120)
CSO hydrolysisc ,0.2 4.7 6 0.3 ,0.2 5.3 6 0.9 4.9 6 0.8 ,0.2
P450 contentd 36.6 6 4.3 34.8 6 3.7 13.9 6 0.8 12.8 6 1.2 24.3 6 4.3 13.2 6 3.0
aReaction rates were determined at a substrate concentration of 128 mM AFB and are given as pmol/min/mg microsomal protein; the value in parentheses is
pmol/min/nmol P450. Control yeast microsomes had no detectable AFB oxidizing activity.
bThe epoxide AFBO was measured by trapping the glutathione-conjugate with a mixture of rat and mouse liver cytosolic GST enzymes as described (Gallager
et al., 1994).
cReaction rates were determined with 50 mM [3H] CSO and are given as nmol diol product/min/mg protein.
dP450 content was determined by CO difference spectra and presented as pmol P450/mg microsomal protein; control yeast microsomes had no detectable P450.
The values for CYP1A/mEH enzymatic activity and P450 content are given as the mean 6 SEM.
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specific enzymatic activities are expressed in terms of reaction
rates per nmol P450 instead of per mg microsomal protein this
difference disappears. While it is difficult to directly compare
cytochrome P450 content and enzymatic activity of CYP1A2
heterologously expressed in yeast with that observed in human
liver, it is worth noting that our yeast P450 content, in terms of
pmol/mg microsomal protein, is within the range observed for
human liver microsomes (Guengerich, 1995). The enzymatic
characteristics of yeast-expressed human mEH towards car-
bamazepine epoxide have been previously described (Eugster
et al., 1991) and are similar to what has been observed for
human liver microsomes. In addition, specific activity towards
cis-stilbene oxide (CSO) was similar for all mEH-expressing
strains with the exception of CYP1A2/DmEH that lacked any
activity (Table 1). However, caution must be used when trying
to draw direct comparisons, since these values are expressed in
terms of reaction rate per mg microsomal protein. Neverthe-
less, as with CYP1A2, mEH expression and activity is not
significantly different from human liver; taking these 2 values
(CYP1A2 and mEH) together would suggest that the ability of
yeast microsomes to activate and hydrolyze AFB might be
within the range seen in human liver.
To determine if mEH expression could offer any protection
against AFB genotoxicity, we analyzed formation of AFB-
DNA adducts in exponentially growing yeast exposed to [3H]
AFB. As seen in Figure 2, expression of CYP1A1 did not
promote adduct formation over background, consistent with
our previous observations that CYP1A1 preferentially forms
AFM and only small amounts of AFBO. Expression of
CYP1A2 resulted in a significant increase of adduct levels over
background with a dose-dependent increase in adduct levels
(5.5 and 11.4 pmol AFB/mg DNA at 0.5 and 1.25 mM AFB,
respectively, Fig. 2). When cells expressing both CYP1A2 and
mEH were exposed to [3H] AFB, they too formed DNA ad-
ducts above background levels, but at 1.25 mM AFB, the levels
of adducts were significantly lowered relative to CYP1A2
alone (4.0 and 3.9 pmol AFB/mg DNA, CYP1A2/mEH and
CYP1A2hi/mEH, respectively; p , 0.05).
To further analyze a possible role for mEH in AFB detoxi-
fication, we studied AFB genotoxicity by 2 separate methods.
The parental yeast strain used for heterologous expression is
diploid and auxotrophic for the amino acid tryptophan due to
mutations in the trp5 alleles. If these 2 alleles undergo mitotic
recombination, gene conversion may occur, allowing yeast to
grow in the absence of tryptophan. As previously described
(Sengstag and Wu¨rgler, 1994) and shown in Figure 3, yeast
expressing CYP1A1 or CYP1A2 undergo gene conversion in
response to AFB exposure in a dose-dependent fashion. When
cells expressing either CYP1A1 and mEH or CYP1A2 and
mEH were exposed to AFB, they too exhibit gene conversion
in a dose dependent manner, but at significantly lower levels
when compared to strains expressing CYP1A1 or CYP1A2
alone (Fig. 3). Furthermore, the inactive mEH mutant was
unable to confer any protection against AFB genotoxicity as
measured by trp5 gene conversion, indicating that enzymatic
activity, rather than some unrelated event associated with mEH
protein expression, is responsible for the reduction in mitotic
recombination. However, if binding to the mEH protein, rather
than catalytic activity, were responsible for the protective
effect of expressed mEH, the null-mEH control experiment
might have underestimated a protective effect in the CYP1A2/
DmEH construct, because Western-blot analysis indicated that
there was somewhat less inactive mEH protein expressed in the
FIG. 2. AFB-DNA adduct formation in yeast expressing CYP1A2 and attenuation by mEH. Cells were exposed to [3H] AFB1, genomic DNA was isolated
and adduct levels quantified by liquid scintillation counting. Yeast expressing CYP1A1 had adduct concentrations comparable to control yeast while
CYP1A2-expressing yeast had adduct concentrations significantly greater than background. *Coexpression of mEH blocked DNA adduction with significant
effect (p , 0.05) at 1.25 mM AFB. Data are mean 6 SEM from samples analyzed in triplicate.
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CYP1A2/DmEH construct, relative to the CYP1A2/mEH con-
struct (Fig. 1).
The role of mEH in AFB genotoxicity was also examined by
Ames assay. When microsomes were isolated from recombi-
nant strains and used as an activating system in the Ames assay
with tester strain TA98, both CYP1A1- and CYP1A2-contain-
ing microsomes were able to cause a dose-dependent increase
in frame-shift mutations as scored by recovery of histidine
revertants (Fig. 4). Similar to what was observed with trp5
gene conversion, coexpression of mEH with either CYP1A1 or
CYP1A2 resulted in significant protection against AFB muta-
genicity, and the catalytically inactive mutant of mEH con-
ferred no protection. For both measures of genotoxicity, mEH
was able to afford a greater degree of protection in cells
expressing CYP1A2, as compared to cells expressing
CYP1A1. This is not surprising, however, because of the
metabolite profiles of CYP1A2 and CYP1A1. CYP1A1 me-
tabolizes AFB almost exclusively to AFM with only minimal
AFBO generation, whereas CYP1A2 forms an approximate 1:1
ratio of AFM and AFBO (Table 1). The carcinogenicity of
AFM in rats is approximately 10% of AFB (Hsieh et al., 1984)
and is generally considered to be a route of detoxification. The
finding that CYP1A1-expressing yeast are able to convert AFB
to a genotoxic metabolite in both the Ames and trp5 gene
conversion assays suggests that AFM is a potent mutagen. To
investigate this further, we exposed control and recombinant
FIG. 3. Modulation of AFB genetic toxicity assessed by mitotic gene conversion at the trp5 locus in intact yeast. Yeast were exposed to the indicated
concentrations of AFB in culture and then plated on tryptophane deficient medium to select for recombinants while plating efficiency/survival was assessed by
plating on complete medium. Intracellular biotransformation of AFB by either CYP1A1 or CYP1A2 resulted in a dose-dependent increase in mitotic
recombination and coexpression with mEH and either P450 attenuated this response. Data are mean 6 SEM from samples of a representative experiment analyzed
in triplicate.
FIG. 4. Activation of AFB by recombinant yeast microsomes to a mutagenic compound in the Ames assay. S. typhimurium tester strain TA 98 was incubated
with AFB and microsomes from the indicated strains as described in Materials and Methods and His1 revertants were scored. CYP1A-containing microsomes
exhibited a dose-dependent increase in AFB mutagenicity, which was decreased by mEH. Statistically significant differences (p , 0.05) for CYP1A1 or CYP1A2
alone versus the respective CYP-containing strain coexpressing mEH are indicated by (*). Data are mean 6 SEM.
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yeast directly to AFM and measured mitotic recombination
rates by trp5 gene conversion in comparison to AFB. As seen
in Figure 5, AFB was significantly more active at inducing
mitotic recombination relative to AFM. In addition, AFM was
not able to induce mitotic recombination in the absence of the
CYP1A enzyme. The ability of yeast-expressed CYP1A en-
zymes to bioactivate AFM was also investigated by incubating
AFM with purified microsomes and analyzing metabolite pro-
duction by HPLC. However, neither CYP1A2 nor CYP1A1
appeared capable of converting AFM to the corresponding
epoxide or other oxidation products (data not shown).
DISCUSSION
In this study, we have demonstrated, for the first time, that
mEH has the ability to confer protection against AFB geno-
toxicity, as measured by DNA-adduct formation, mitotic re-
combination and Ames assay mutagenicity in doubly trans-
fected yeast. Although previous studies have failed to
demonstrate a protective role of human mEH in AFB-induced
genotoxicity (Guengerich et al., 1996; Johnson et al., 1997b;
Wilson et al., 1997), there are substantial methodological dif-
ferences between this study and the previous studies. In this
study, we investigated mEH function in an intact cell system
where, with the exception of the Ames assay, the reactive
metabolite AFBO was generated in situ, where both CYP and
mEH enzymes colocalized to the same subcellular compart-
ment. In the study of Wilson et al. (1997), the researchers were
investigating sister chromatid exchange (SCE) in peripheral
lymphocytes exposed to AFB and human liver microsomes of
varying CYP1A2 and mEH phenotype (i.e., supposed varying
activation and detoxification activities, respectively). Perhaps
SCE is not a very reliable measure of AFB genotoxicity, given
the fact that they saw only a very modest protection (;2-fold
decreased genotoxicity) in lymphocytes exposed to AFB and
mouse liver microsomes in the presence or absence of mouse
liver cytosol. The presence of mGstA3-3 in mouse liver cytosol
would be expected to significantly decrease AFB genotoxicity
but this was not observed. Since we believe that mEH has only
a modest effect on AFB genotoxicity, and mGstA3-3 is capable
of greatly reducing AFB genotoxicity, it is not surprising that
Wilson et al. were unable to find an association between mEH
phenotype (based on CSO activity) and rates of SCE.
The kinetic studies of Guengerich et al. (1996) were con-
ducted with bacterially expressed CYP3A4 and purified rat or
human mEH that were subsequently reconstituted in vitro. This
study found that only at very high ratios of mEH to CYP3A4
could mEH alter AFB genotoxicity as assessed by umu re-
sponse in S. typhimurium tester strain TA1535. The experi-
ments by Johnson et al. (1997b) found that the rate of hydro-
lysis of AFBO was unaffected by addition of purified human
mEH while purified rat mEH was able to slightly increase the
hydrolysis rate.
Significant differences exist between those experiments and
this current study. First, we are using CYP1A2, not CYP3A4,
and in our case the enzyme-coding sequence (i.e., deletion of
N-terminal membrane anchor) has not been altered to facilitate
expression in E. coli; however, these differences are not likely
to be of major importance. Second, we are expressing mEH
and CYP1A2 together so they colocalize without any mem-
brane reconstitution utilizing synthetic lipids. Finally, in our
recombinant yeast, the AFBO is generated in the endoplasmic
reticulum (a hydrophobic environment) which may protect the
CYP-generated AFBO from non-enzymatic hydrolysis.
Because mEH and CYP enzyme are localized to the same
subcellular compartment, mEH may well be positioned to
facilitate hydrolysis of AFBO near its intracellular site of
formation. Although it is conceptually difficult to understand
how the hydrophobic environment of the endoplasmic reticu-
lum could effectively protect CYP-generated exo-AFBO from
the high concentration of intracellular water present in the
intact cell or sub-cellular fractions, this must indeed occur,
because numerous studies have previously demonstrated the
effectiveness of certain glutathione S-transferases with high
efficiency toward AFBO to effectively compete with water for
the highly reactive exo-AFBO (Buetler et al., 1992; Ch’ih et
al., 1983b; Guengerich et al., 1996; Raney et al., 1992a,b;
Gallagher et al., 1994; Johnson et al., 1997a). Thus, in the
absence of an effective glutathione conjugation system such as
occurs in the mouse, and to a lesser extent in rat liver, mEH
activity may play a functional role in protection of DNA
against the reactive AFB-exo-8,9-oxide. Because primate
GSTs, including human, have very low AFBO-conjugating
activity (Raney et al., 1992b; Johnson et al., 1997a; Wang et
al., 2000) relative to that seen in rodent liver (Buetler et al.,
FIG. 5. Comparison of mitotic recombination induced by AFB or AFM.
Yeast was exposed to equal concentrations of either AFB or AFM and then
mitotic recombination scored by reversion of tryptophan auxotrophy. AFM
induced mitotic recombination in cells expressing either CYP1A1 or CYP1A2
to levels above background but the values were not statistically significant.
Statistically significant differences (p , 0.05) between yeast expressing no
cDNA versus CYP1A1 or CYP1A2 are indicated by an (*). Data are mean 6
SEM from 2 separate experiments, each analyzed in triplicate (n 5 6).
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1992; Van Ness et al., 1998), mEH may provide important
protection against AFB-induced DNA damage in the human
liver.
The observation that CYP1A1 was capable of converting
AFB to a mutagenic metabolite in both intact yeast (trp5 gene
conversion) and in purified microsomes (Ames assay) is puz-
zling since CYP1A1 forms AFM at a high rate but generates
little AFBO and forms no detectable DNA adducts. However,
the acute toxicity of AFM in rats is actually close to what one
sees with AFB (Pong and Wogan, 1971). We tested the pos-
sibility that CYP1A1 or an endogenous enzyme is further
metabolizing AFM to a genotoxic compound. Exposure of
yeast to purified AFM only induced a slight increase in trp5
gene conversion in CYP1A-expressing cells while incubation
of AFM with microsomes expressing CYP1A1 or CYP1A2
yielded no detectable metabolites. The low rate of mitotic
recombination may be a result of poor permeability of AFM
through the yeast cell wall. Previously, it was shown that
human liver microsomes were capable of bioactivating AFM to
the corresponding epoxide (Neal et al., 1998). In contrast to
these findings, we were unable to detect such a metabolite,
either with yeast-expressed CYP1A1 or CYP1A2 or with sev-
eral different human liver microsome preparations. The rea-
sons for this are not clear but may be due to sensitivity of the
assay. The fact that CYP1A1 is capable of forming a muta-
genic metabolite (as assessed by Ames assay mutagenicity and
reversion of tryptophan prototrophy) and that mEH attenuates
this response would seem to imply that an epoxide intermediate
is involved, although quantity is very small, relative to the
amount of AFM1 formed, and is below the limit of detection of
our HPLC-based assay.
In conclusion, we have provided several lines of evidence
that coexpression of mEH is capable of modifying the geno-
toxic properties of AFB, thus supporting the epidemiological
correlation that differences in mEH activity due to genetic
polymorphisms can alter the risk of AFB-induced hepatocel-
lular carcinoma (McGlynn et al., 1995). The use of recombi-
nant yeast to recreate a multi-step biotransformation pathway
facilitated this finding in a manner not utilized in previous
studies, which found no significant role for mEH in AFB
metabolism. Finally, because human gene products are readily
expressed and function in yeast in a manner similar to higher
organisms, they provide a useful system for testing the func-
tional significance of sequential human biotransformation en-
zymes involved in multistep xenobiotic activation and detoxi-
fication.
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